PL2837632T3 - Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych - Google Patents
Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnychInfo
- Publication number
- PL2837632T3 PL2837632T3 PL13784533T PL13784533T PL2837632T3 PL 2837632 T3 PL2837632 T3 PL 2837632T3 PL 13784533 T PL13784533 T PL 13784533T PL 13784533 T PL13784533 T PL 13784533T PL 2837632 T3 PL2837632 T3 PL 2837632T3
- Authority
- PL
- Poland
- Prior art keywords
- triazabicyclo
- octane
- derivatives
- useful
- treatment
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210109743 | 2012-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2837632T3 true PL2837632T3 (pl) | 2017-01-31 |
Family
ID=49514204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13784533T PL2837632T3 (pl) | 2012-04-13 | 2013-04-09 | Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9090623B2 (pl) |
| EP (1) | EP2837632B1 (pl) |
| JP (1) | JP5925381B2 (pl) |
| KR (1) | KR101673979B1 (pl) |
| CN (1) | CN104334561B (pl) |
| PL (1) | PL2837632T3 (pl) |
| WO (1) | WO2013163917A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107812195B (zh) * | 2014-09-04 | 2021-04-20 | 连云港金康和信药业有限公司 | (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物 |
| US10398697B2 (en) | 2014-09-04 | 2019-09-03 | Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. | Solid solution comprising (6S)-5-methyl tetrahydrofolic acid or salt thereof, and preparation and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5124452A (en) * | 1978-07-10 | 1992-06-23 | Bioresearch S.P.A. | Process for producing d,1-5-methyltetrahydrofolic acid and its salts |
| CH681303A5 (pl) | 1991-01-16 | 1993-02-26 | Eprova Ag | |
| DE4136921A1 (de) * | 1991-11-11 | 1993-05-13 | Knoll Ag | Verfahren zur trennung von 5-methyl-tetrahydrofolsaeure |
| CH686369A5 (de) | 1994-05-09 | 1996-03-15 | Eprova Ag | Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure. |
| CH693905A5 (de) * | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
| PT1392307E (pt) | 2001-05-14 | 2005-11-30 | Pfizer Prod Inc | Sais tartarato de 5,8,14-triazatetraciclo-[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno |
| NZ528209A (en) | 2001-05-14 | 2004-09-24 | Pfizer Prod Inc | The citrate salt of 5, 8, 14-triazatetracyclo (10.3.1.02,11.04.9)-hexadeca-2.(11),3,5,7,9-pentaene |
| DE60209929T2 (de) | 2001-11-29 | 2006-11-16 | Pfizer Products Inc., Groton | Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen |
| PT1448235E (pt) | 2001-11-30 | 2007-05-31 | Pfizer Prod Inc | Composições farmacêuticas orais de libertação controlada de 5,8,14-triazatetraciclo ( 10.3.1.0(2,11).0(4,9) ) - hexadeca-2(11),3,5,7,9-pentaeno. |
| SE0303526D0 (sv) * | 2003-12-22 | 2003-12-22 | Biofol Ab | Chemotherapeutic agents |
| CN101143863B (zh) * | 2006-09-13 | 2010-08-11 | 南京莱因医药科技有限公司 | 5-甲基四氢叶酸的拆分及其成盐方法 |
| EP2376499B1 (en) | 2008-12-11 | 2015-02-25 | Cti Biopharma Corp. | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
| CN101781637B (zh) | 2009-01-16 | 2012-09-05 | 中国科学院生物物理研究所 | 人源5,10-次甲基四氢叶酸合成酶及其复合物的结晶方法、晶体以及应用 |
-
2013
- 2013-04-09 KR KR1020147030853A patent/KR101673979B1/ko active Active
- 2013-04-09 EP EP13784533.5A patent/EP2837632B1/en active Active
- 2013-04-09 PL PL13784533T patent/PL2837632T3/pl unknown
- 2013-04-09 JP JP2015504854A patent/JP5925381B2/ja active Active
- 2013-04-09 CN CN201380019596.3A patent/CN104334561B/zh active Active
- 2013-04-09 US US14/394,434 patent/US9090623B2/en active Active
- 2013-04-09 WO PCT/CN2013/073959 patent/WO2013163917A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2837632A1 (en) | 2015-02-18 |
| EP2837632A4 (en) | 2015-10-14 |
| JP2015513360A (ja) | 2015-05-11 |
| WO2013163917A1 (zh) | 2013-11-07 |
| KR101673979B1 (ko) | 2016-11-08 |
| EP2837632B1 (en) | 2016-05-18 |
| US9090623B2 (en) | 2015-07-28 |
| JP5925381B2 (ja) | 2016-05-25 |
| CN104334561B (zh) | 2016-06-22 |
| KR20140143437A (ko) | 2014-12-16 |
| US20150065708A1 (en) | 2015-03-05 |
| CN104334561A (zh) | 2015-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1900040I1 (hu) | Makrociklusos származékok proliferatív betegségek kezelésére | |
| HUS2200017I1 (hu) | Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére | |
| IL231591A0 (en) | Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases | |
| IL230635A (en) | An outgrowth of 4,3,2,1-tetrahydroquinoline used to treat diabetes | |
| LT2838539T (lt) | Estrogeniniai dariniai, skirti naudoti neurologinių sutrikimų gydymui | |
| EP2967049A4 (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
| PL2726470T3 (pl) | Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych | |
| PL392436A1 (pl) | Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego | |
| HUP1100290A2 (en) | Combination compositions for the treatment of proliferative diseases | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| PL2837632T3 (pl) | Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych | |
| PL395469A1 (pl) | Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego | |
| HK1193343A (en) | Methods for treating diseases of the retina | |
| PL399422A1 (pl) | Sposób wytwarzania 2',4,4',6'-tetrahydroksydihydrochalkonu | |
| PL399423A1 (pl) | Sposób wytwarzania 2'-hydroksydihydrochalkonu | |
| PL398695A1 (pl) | Sposób wytwarzania 2'-hydroksydihydrochalkonu | |
| HK1188955A (en) | Methods for treating diseases of the retina | |
| HK1189818A (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| HK1197236B (en) | Compounds for the treatment of addiction | |
| HK1192488A (zh) | 用作治疗法布瑞氏症的给药方案 |